Skip Navigation


JAC Advance Access originally published online on September 9, 2005
Journal of Antimicrobial Chemotherapy 2005 56(5):869-871; doi:10.1093/jac/dki295
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/5/869    most recent
dki295v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mota-Meira, M.
Right arrow Articles by Lavoie, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mota-Meira, M.
Right arrow Articles by Lavoie, M. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

In vivo activity of mutacin B-Ny266

Marilaine Mota-Meira1, Helene Morency2 and Marc C. Lavoie1,2,*

1 Department of Biological and Chemical Sciences, Faculty of Pure and Applied Sciences, The University of the West Indies, Cave Hill Campus, PO Box 64, Bridgetown, Barbados; 2 Département de Biochimie et Microbiologie, Faculté des Sciences et de Génie, Université Laval, Québec, Canada

Received 4 May 2005; returned 11 June 2005; revised 12 July 2005; accepted 26 July 2005

* Corresponding author. Tel: +246-417-4354; Fax: +246-417-4325; E-mail: mlavoie{at}uwichill.edu.bb

Objectives: The objective of this study was to assess the in vivo activity of mutacin B-Ny266 (a bacteriocin produced by Streptococcus mutans) in order to eventually use it as an antibiotic.

Methods: Intraperitoneal infection was induced with a methicillin-susceptible Staphylococcus aureus strain in mice. Some of the mice were simultaneously injected intraperitoneally with mutacin B-Ny266, some with the vehicle only and some with vancomycin.

Results: While there was 70 and 100% mortality in the control groups of mice, no mortality was observed in the mice injected with vancomycin or mutacin B-Ny266.

Conclusions: The results presented here show, for the first time, the in vivo efficacy of a mutacin (B-Ny266) against an experimental intraperitoneal infection by S. aureus in a mouse model.

Keywords: antimicrobial peptides , lantibiotics , Streptococcus mutans , MIC , MBC


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
S. C. Corr, Y. Li, C. U. Riedel, P. W. O'Toole, C. Hill, and C. G. M. Gahan
From the Cover: Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118
PNAS, May 1, 2007; 104(18): 7617 - 7621.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
A. P. Anisimov and K. K. Amoako
Treatment of plague: promising alternatives to antibiotics.
J. Med. Microbiol., November 1, 2006; 55(Pt 11): 1461 - 1475.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.